We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
-2.14%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$93.7M
AUM Growth
-$14.2M
Cap. Flow
-$5.83M
Cap. Flow %
-6.22%
Top 10 Hldgs %
66.44%
Holding
48
New
3
Increased
5
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$2.02M
2
MRUS
Merus
MRUS
+$1.48M
3
ZLAB icon
Zai Lab
ZLAB
+$967K
4
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$519K
5
BCYC
Bicycle Therapeutics
BCYC
+$391K

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.5M
2
NMRA icon
Neumora Therapeutics
NMRA
+$871K
3
ILMN icon
Illumina
ILMN
+$374K
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$187K
5
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$85.9K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILMN icon
1
Illumina
ILMN
$29.5B
$12.4M 13.27%
119,196
-3,337
-3% -$374K
HRMY icon
2
Harmony Biosciences
HRMY
$2.08B
$11.1M 11.87%
368,665
– –
MRUS
3
DELISTED
Merus
MRUS
$7.1M 7.58%
120,038
+30,522
+34% +$1.48M
GERN icon
4
Geron
GERN
$898M
$5.82M 6.21%
1,373,550
+49,000
+4% +$191K
OCS icon
5
Oculis Holding
OCS
$655M
$5.21M 5.56%
436,378
– –
INCY icon
6
Incyte
INCY
$25.4B
$4.49M 4.79%
74,022
– –
EXAI
7
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$4.39M 4.68%
859,892
– –
XENE icon
8
Xenon Pharmaceuticals
XENE
$6.1B
$4.16M 4.44%
106,680
– –
LBPH
9
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$3.91M 4.17%
144,570
+26,315
+22% +$519K
MIRM icon
10
Mirum Pharmaceuticals
MIRM
$6.56B
$3.63M 3.87%
106,100
+10,000
+10% +$262K
LAB icon
11
Standard BioTools
LAB
$342M
$3.33M 3.56%
1,883,179
– –
ONC
12
BeOne Medicines Ltd
ONC
$33.9B
$3.28M 3.5%
23,022
– –
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$2.58M 2.76%
219,277
– –
RYTM icon
14
Rhythm Pharmaceuticals
RYTM
$7.31B
$2.02M 2.15%
49,120
– –
TRML
15
DELISTED
Tourmaline Bio
TRML
$1.89M 2.01%
146,800
+125,813
+599% +$2.02M
RANI icon
16
Rani Therapeutics
RANI
$94.8M
$1.88M 2%
493,584
– –
ASND icon
17
Ascendis Pharma A/S
ASND
$16.5B
$1.85M 1.98%
13,600
– –
REPL icon
18
Replimune Group
REPL
$454M
$1.84M 1.97%
204,939
– –
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$4.51B
$1.67M 1.79%
102,984
– –
MDGL icon
20
Madrigal Pharmaceuticals
MDGL
$12.6B
$1.59M 1.7%
5,682
– –
EXEL icon
21
Exelixis
EXEL
$13.9B
$1.44M 1.54%
64,200
– –
ZLAB icon
22
Zai Lab
ZLAB
$2.07B
$953K 1.02%
+55,000
New +$967K
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.9B
$890K 0.95%
10,815
– –
BOLT icon
24
Bolt Biotherapeutics
BOLT
$7.4M
$875K 0.93%
58,348
– –
TRDA icon
25
Entrada Therapeutics
TRDA
$254M
$699K 0.75%
49,082
– –
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q2 2024 Portfolio in Review

As of Q2 2024, Nan Fung Group Holdings held 48 positions worth $93.7M, down 13% from $108M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Nan Fung Group Holdings withdrew a net $5.83M in Q2 2024, closing 4 positions and reducing 1 holding. Its most notable exit was Alpine Immune Sciences Inc, an estimated $10.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Nan Fung Group Holdings opened a new position in Zai Lab worth $953K.

  • Nan Fung Group Holdings's largest Q2 2024 buy was Zai Lab: 55,000 shares worth $953K.
  • Nan Fung Group Holdings added most to Tourmaline Bio in Q2 2024, an estimated $2.02M increase.
  • Nan Fung Group Holdings's biggest Q2 2024 reduction was Illumina, cutting an estimated $374K.
  • Nan Fung Group Holdings fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $10.5M.
  • Nan Fung Group Holdings's ten largest holdings make up 66% of its $93.7M portfolio in Q2 2024.
  • Nan Fung Group Holdings opened 3 new positions and closed 4 in Q2 2024.
  • Nan Fung Group Holdings's portfolio value fell 13% quarter-over-quarter to $93.7M.

Based on Nan Fung Group Holdings's 13F filing for Q2 2024, filed 13 Aug 2024.